Nontuberculous mycobacterial lung disease caused by <i>Mycobacterium avium</i> complex - disease burden, unmet needs, and advances in treatment developments

Key advancements in NTM-LD management include recent updates to clinical practice guidelines, approval of ALIS for the treatment of refractory MAC-LD, and ongoing clinical trials of investigational treatments. Yet opportunities still exist to improve patient outcomes, including development of better screening tools, such as reliable and responsive biomarkers to help identify high-risk patients, and addressing unmet treatment needs.